iData Insights

Lung Adenocarcinoma - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 29, 2016 15:10 IST

Lung Adenocarcinoma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Lung Adenocarcinoma - Pipeline Review, H2 2015 , provides an overview of the Lung Adenocarcinoma s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Lung Adenocarcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 8

Global Markets Direct Report Coverage 8

Lung Adenocarcinoma Overview 9

Therapeutics Development 10

Pipeline Products for Lung Adenocarcinoma - Overview 10

Pipeline Products for Lung Adenocarcinoma - Comparative Analysis 11

Lung Adenocarcinoma - Therapeutics under Development by Companies 12

Lung Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 14

Lung Adenocarcinoma - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Lung Adenocarcinoma - Products under Development by Companies 18

Lung Adenocarcinoma - Products under Investigation by Universities/Institutes 19

Lung Adenocarcinoma - Companies Involved in Therapeutics Development 20

Amgen Inc. 20

Astex Pharmaceuticals, Inc. 21

AstraZeneca Plc 22

AVEO Pharmaceuticals, Inc. 23

Axelar AB 24

Bayer AG 25

Boehringer Ingelheim GmbH 26

Eisai Co., Ltd. 27

Genentech, Inc. 28

Hanmi Pharmaceuticals, Co. Ltd. 29

Immunomedics, Inc. 30

Incyte Corporation 31

Johnson & Johnson 32

Morphotek, Inc. 33

Pfizer Inc. 34

Sanofi 35

VG Life Sciences, Inc. 36

Vichem Chemie Research Ltd. 37

Lung Adenocarcinoma - Therapeutics Assessment 38

Assessment by Monotherapy Products 38

Assessment by Combination Products 39

Assessment by Target 40

Assessment by Mechanism of Action 43

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

afatinib dimaleate - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

AV-203 - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

AXL-1717 - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

AZD-6738 - Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

BAY-1163877 - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

dacomitinib - Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

DBPR-112 - Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

EB-102 - Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

farletuzumab - Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

hydroxychloroquine + sorafenib tosylate - Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

JNJ-42756493 - Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

lenvatinib - Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

MAG-Tn3 - Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

poziotinib - Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases - Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

ruxolitinib phosphate - Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

SAR-408701 - Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Small Molecule for Cancer - Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Small Molecule to Inhibit EGFR for Non-Small Cell Lung Cancer and Lung Adenocarcinoma - Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

SNX-5422 - Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

solitomab - Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

TdCyd - Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

Vaccine for Oncology - Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Vaccine to Target CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

VAL-401 - Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Lung Adenocarcinoma - Recent Pipeline Updates 99

Lung Adenocarcinoma - Dormant Projects 129

Lung Adenocarcinoma - Product Development Milestones 130

Featured News & Press Releases 130

May 29, 2015: Spectrum Pharmaceuticals Highlights Abstract of Clinical Data For Poziotinib at the 2015 ASCO Annual Meeting 130

Appendix 131

Methodology 131

Coverage 131

Secondary Research 131

Primary Research 131

Expert Panel Validation 131

Contact Us 131

Disclaimer 132"

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects